Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 9;13:825364. doi: 10.3389/fimmu.2022.825364

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Wang, Zhang, Anderson, Lamble and Orentas

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Anti-CD22 CAR-T mediated cellular cytotoxicity (CTL) of bryostatin-treated leukemia. (A–D) Average lysis from triplicate wells for four cell lines (Raji, NALM6, REH, and K562) by anti-CD22 CART (CD22 CART, open circle) or un-transduced T cells from the same donor (UTD, open triangle), treated with bryostatin (+B, closed shape) or untreated (open shape), a the E:T ratios listed on the x-axis. (E–H) Assay tested in parallel including cold-target inhibition (addition of K562 at a 30:1 E:T ratio). Representative results for T cells from 3 donors are shown, each data point showing the average and standard deviation from three replicate wells.